D-galactose supplement for SLC35A2-CDG symptoms
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a sugar called D-galactose given as a supplement to help with symptoms of SLC35A2-CDG, a rare genetic condition that can cause seizures and digestive problems. The goal is to see if taking this sugar improves those symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed change in the SLC35A2 gene from a genetic test
- Patient is older than 1 month
- Has at least one of these symptoms: seizures, chronic vomiting, chronic constipation, or chronic diarrhea
- A parent or guardian can give permission (for minors or adults who can't consent)
- Females over age 8 must use birth control
- Had an eye exam within the past year
- Cannot have galactosemia or aldolase-B deficiency, and must not have had serious reactions to galactose before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a sugar called D-galactose to see if it is safe and works well for people with PGM1-CDG, a rare genetic condition that affects how the body uses sugar. If you are already taking D-galactose, this trial will check if it helps your symptoms.
This trial tests whether taking fucose (a type of sugar) can help people with GLUT1 deficiency syndrome, a rare genetic condition that affects how the brain gets energy. If you have ataxia (trouble with balance or coordination) and meet other criteria, this study may be an option for you.
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
This study tests a drug called phenylbutyrate for people with seizures caused by SLC6A1 gene changes. The drug may help reduce seizure frequency. The trial is fully remote, so you can join from anywhere in the U.S. without going to a clinic.
This early (Phase 1) study tests how adding specific dietary supplements affects “protein glycosylation,” which means how sugar molecules attach to proteins in your blood. It’s meant to see how the supplements change these blood measurements and whether the approach is tolerable in generally healthy adults.
Hear when a new SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.